Bevacizumab fails to treat temporal paraganglioma: Discussion and case illustration

Journal of Neuro-Oncology

Volumn 98, Issue 3, 2010, Pages 427-430

  Aliabadi, Hamidreza ^a   Vredenburgh, James J ^a   Everson, Richard G ^a   Desjardins, Annick ^a   Friedman, Henry S ^a   McLendon, Roger E ^a   Tucci, Debara L ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Glomus jugulare; Glomus tumors; Temporal paraganglioma

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ADULT; ARTICLE; AUDIOGRAPHY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GLOMUS JUGULARE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PERCEPTION DEAFNESS; POSITIONAL DIZZINESS; SPEECH DISCRIMINATION; TEMPORAL LOBE; TINNITUS; TUMOR CELL; TUMOR VOLUME;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; TEMPORAL LOBE; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953609807     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0091-2     Document Type: Article

References (24)

1. J Heth 2004 The basic science of glomus jugulare tumors Neurosurg Focus 17 2 E2 10.3171/foc.2004.17.2.2 15329017
2. EC Mariman, et al. 1993 Analysis of a second family with hereditary non-chromaffin paragangliomas locates the underlying gene at the proximal region of chromosome 11q Hum Genet 91 4 357 361 10.1007/BF00217356 1:STN:280:DyaK3s3ntlejsA%3D%3D 8388849
3. EE Lack, et al. 1977 Paragangliomas of the head and neck region: a clinical study of 69 patients Cancer 39 2 397 409 10.1002/1097-0142(197702)39: 2<397::AID-CNCR2820390205>3.0.CO;2-C 1:STN:280:DyaE2s7htlOhsQ%3D%3D 837327
4. CG Jackson 2001 Glomus tympanicum and glomus jugulare tumors Otolaryngol Clin North Am 34 5 941 970 10.1016/S0030-6665(05)70356-X 1:STN:280: DC%2BD3MrhtVehtw%3D%3D 11557448 vii (Pubitemid 33000982)
5. WC Mertens DJ Grignon W Romano 1993 Malignant paraganglioma with skeletal metastases and spinal cord compression: response and palliation with chemotherapy Clin Oncol (R Coll Radiol) 5 2 126 128 1:STN:280: DyaK3s3ksVansg%3D%3D
6. SR Patel DJ Winchester RS Benjamin 1995 A 15-year experience with chemotherapy of patients with paraganglioma Cancer 76 8 1476 1480 10.1002/1097-0142(19951015)76:8<1476::AID-CNCR2820760827>3.0.CO;2-9 1:STN:280:DyaK283itlajtg%3D%3D 8620426
7. N Ferrara, et al. 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 5 391 400 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D 15136787
8. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1182 1186 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D 4938153
9. J Favier, et al. 2002 Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors Am J Pathol 161 4 1235 1246 1:CAS:528:DC%2BD38Xotl2jsr8%3D 12368197
10. K Takekoshi, et al. 2004 Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas Life Sci 74 7 863 871 10.1016/j.lfs.2003.07.036 1:CAS:528:DC%2BD3sXps1Gqs7o%3D 14659975 (Pubitemid 37501135)
11. M Shibuya 2006 Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis J Biochem Mol Biol 39 5 469 478 1:CAS:528:DC%2BD28XhtFWqsb3M 17002866
12. JR Tonra DJ Hicklin 2007 Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy Immunol Invest 36 1 3 23 10.1080/08820130600991794 1:CAS:528:DC%2BD2sXhsFCju7w%3D 17190647 (Pubitemid 46024914)
13. K Salmenkivi, et al. 2003 VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome Apmis 111 4 458 464 10.1034/j.1600-0463.2003.1110402.x 12780519 (Pubitemid 36735003)
14. G Ranieri, et al. 2006 Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic Curr Med Chem 13 16 1845 1857 10.2174/092986706777585059 1:CAS:528:DC%2BD28Xms1CltrY%3D 16842197
15. A Zielke, et al. 2002 VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors Surgery 132 6 1056 1063 10.1067/msy.2002. 128613 12490855 discussion 1063 (Pubitemid 36026955)
16. HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 21 4368 4380 10.1200/JCO.2002.10.088 1:CAS:528:DC%2BD38Xpt1CjtL0%3D 12409337 (Pubitemid 35266299)
17. S Senan EF Smit 2007 Design of clinical trials of radiation combined with antiangiogenic therapy Oncologist 12 4 465 477 10.1634/theoncologist.12-4-465 1:CAS:528:DC%2BD2sXmtlSitrc%3D 17470689 (Pubitemid 46698724)
18. H Hurwitz, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
19. FF Kabbinavar, et al. 2005 Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 16 3697 3705 10.1200/JCO.2005.05.112 1:CAS:528:DC%2BD2MXlslWntr0%3D 15738537
20. T Shih C Lindley 2006 Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin Ther 28 11 1779 1802 10.1016/j.clinthera. 2006.11.015 1:CAS:528:DC%2BD2sXhtVClsbg%3D 17212999 (Pubitemid 46038527)
21. RK Jain, et al. 2007 Angiogenesis in brain tumours Nat Rev Neurosci 8 8 610 622 10.1038/nrn2175 1:CAS:528:DC%2BD2sXnvFKntbk%3D 17643088 (Pubitemid 47093931)
22. Y Wang, et al. 2004 Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro Angiogenesis 7 4 335 345 10.1007/s10456-004-8272-2 1:CAS:528:DC%2BD2MXktVajtL4%3D 15886877 (Pubitemid 40767935)
23. ET Shinohara A Maity 2009 Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment Curr Mol Med 9 9 1034 1045 10.2174/156652409789839107 1:CAS:528:DC%2BC3cXhsFeisbw%3D 19938317
24. CG Willett, et al. 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2 145 147 10.1038/nm988 1:CAS:528:DC%2BD2cXoslKmtQ%3D%3D 14745444 (Pubitemid 38524883)